Viking Therapeutics, Inc.(股票代码:VKTX)今日盘中大涨8.59%,市值一度突破10亿美元,引发市场关注。分析人士认为,这与多家制药巨头公开反对诺和诺德(Novo Nordisk)收购合同药品生产商康泰伦特(Catalent Inc)有关。
为何反对此次收购引发关注?诺和诺德作为全球肥胖症药物龙头企业,此次欲以160亿美元收购康泰伦特,目的是扩大自身在减肥药领域的研发和生产实力。但罗氏、礼来、阿斯利康等巨头公开表示反对,称这将限制减肥药行业的竞争环境,不利于整个行业长远发展。
作为一家专注于开发肥胖症和非酒精性脂肪性肝炎药物的生物科技公司,Viking Therapeutics被视为减肥药市场的潜在受益者。如果诺诺德的收购案最终被阻止,有利于维护减肥药市场的竞争环境,从而对Viking Therapeutics等小型公司的长远发展形成利好。因此,相关预期推动Viking Therapeutics股价今日大涨。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.